Sartorius Stedim Biotech

DIM

Equity

ISIN FR0013154002 / Valor 32518471

Euronext - Euronext Paris (2024-09-17)

EUR 181.50-0.49%

Sartorius Stedim Biotech
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Sartorius Stedim Biotech is a key player in the biopharmaceutical industry, offering a wide range of products and services to help customers streamline their production processes and enhance the manufacturing of biotech medications and vaccines. With a global presence and a workforce of over 10,600 employees, the company provides innovative technologies for cell line development, cell culture media, bioreactors, and various products for the separation, purification, and concentration of biological substances. Sartorius Stedim Biotech is a subsidiary of Sartorius Stedim Biotech S.A., headquartered in France and listed on the Euronext stock exchange in Paris.

Summarized from source with an LLMView SourceSector: Healthcare

Sales Revenue

In the first half of 2024, Sartorius Stedim Biotech reported sales revenue of 1,373 million euros. This represents an organic decline of 3.8 percent in constant currencies and 1.2 percent including acquisitions. However, the second quarter saw a 4.7 percent revenue growth in constant currencies.

Underlying EBITDA

Sartorius Stedim Biotech's underlying EBITDA for the first half of 2024 stood at 387 million euros, resulting in a margin of 28.2 percent. This marks a decline of 6.8 percent compared to the previous year, primarily due to volume and product mix effects.

Net Profit

The net profit for Sartorius Stedim Biotech in the first half of 2024 was 104 million euros, down from 244 million euros in the same period of the previous year. Underlying net profit was 165 million euros, compared to 242 million euros in the first half of 2023.

Equity and Debt

As of June 30, 2024, Sartorius Stedim Biotech's equity was 3,924 million euros, with an equity ratio of 48.6 percent. Gross debt decreased to 2,919 million euros, and net debt stood at 2,465 million euros, resulting in a net debt to underlying EBITDA ratio of 3.3.

Outlook for 2024

Sartorius Stedim Biotech has adjusted its outlook for the remainder of 2024, expecting sales revenue to be roughly at the prior-year level. The company now projects an underlying EBITDA margin of 27 to 29 percent for the full year, down from the previous forecast of above 30 percent.

Summarized from source with an LLMView Source

Key figures

-28.5%1Y

-65.3%3Y

38.4%5Y

Performance

50.1%1Y

47.1%3Y

44.1%5Y

Volatility